Accelerating Early Phase Clinical Development in the UK:

Posted:
24
October 2011

The Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI) welcomes you to attend its annual meeting being held on Friday 18th November at the Wellcome Collection Conference Centre, London from 13h30 to 17h30.The Association has been in existence for over nearly 2 decades and has forged links with both other scientific societies with similar interests and with professional bodies such as the ABPI and ICR. The AHPPI's mission is to offer a framework for discussion and to exchange on current topics in applied Human Pharmacology and early phase drug development. Its aim is also to provide training, education and guidance and provide a forum for innovation and the development of new methods and efficiencies.The topic of this meeting will focus on "Accelerating Early Phase Clinical Development in the UK", and as always we expect to have a panel of excellent speakers from such organisations as ABPI, MHRA, NHS, pharmaceutical and CRO industries. For further details for what's in store for the day, please click here to view the full meeting agenda or here to register.Furthermore there will be the opportunity to attend the guided tours of the Wellcome collections and exhibitions. If you are interested in attending a tour on the day of the AHPPI meeting, please contact us for more details.This meeting has been awarded four Continuing Professional Development points by the Faculty of Pharmaceutical Medicine and is open to AHPPI members and non-members. On behalf of the AHPPI we cordially invite you to attend and look forward to seeing you next month!

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more